Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01285
|
|||||
| Drug Name |
Ixabepilone
|
|||||
| Synonyms |
Azaepothilone B; BMS-247550; Ixempra (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H42N2O5S
|
|||||
| Canonical SMILES |
CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C
|
|||||
| InChI |
InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
|
|||||
| InChIKey |
FABUFPQFXZVHFB-PVYNADRNSA-N
|
|||||
| CAS Number |
CAS 219989-84-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 506.7 | Topological Polar Surface Area | 140 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11969810
, 14786763
, 14933557
, 34184371
, 47206488
, 49684213
, 49999545
, 57369862
, 76567192
, 91148449
, 103771488
, 114573104
, 126623101
, 126665598
, 127325936
, 127325937
, 127325938
, 127325939
, 134223036
, 135135146
, 135610851
, 137240334
, 137248706
, 140173305
, 152258135
, 160646974
, 162202446
, 175267394
, 176484667
, 178103430
, 179150167
, 184022005
, 184529017
, 184812276
, 221678841
, 223664545
, 226399596
, 228058699
, 241053227
, 248880927
, 251910828
, 252448545
|
|||||
| ChEBI ID |
CHEBI:63605
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ixabepilone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.